1 Beaten-Down Stock With 10X Potential

Motley Fool2021-10-15

Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

replaygoh
2021-10-17
replaygoh
okok
SanWangtikup
2021-10-15
SanWangtikup
Like pls
- JeremyKok:
  hi. please like and comment back. thank you.
breAkdaWn
2021-10-15
breAkdaWn
Better take Xanax!
carchoo
2021-10-15
carchoo
Ok cool
Abbas99m
2021-10-15
Abbas99m
Okay
- 滚股怪:
  Okly
Cvt
2021-10-15
Cvt
Good

发表看法

160

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2175194207?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-15 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2175194207","market":"us","top_or_hot":-1,"title":"1 Beaten-Down Stock With 10X Potential","media":"Motley Fool","content":"<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","article_id":"2175194207","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","pubTimestamp":1634264640,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"This biotech is down, but it isn't out just yet.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"translate_title":"1个10倍潜力的被击倒的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9},"content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":827360181,"gmtCreate":1634421612906,"gmtModify":1634421613904,"author":{"id":"3582963095283492","authorId":"3582963095283492","name":"replaygoh","avatar":"https://static.tigerbbs.com/d47b21291424a3d55039334a8de5cdb9","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"okok","listText":"okok","text":"okok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827360181","repostId":2175194207,"repostType":4,"repost":{"id":"2175194207","pubTimestamp":1634264640,"share":"https://www.laohu8.com/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":824142239,"gmtCreate":1634295303188,"gmtModify":1634295303428,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824142239","repostId":2175194207,"repostType":4,"repost":{"id":"2175194207","pubTimestamp":1634264640,"share":"https://www.laohu8.com/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6215367,"gmtCreate":1634339409920,"gmtModify":1634634517898,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":824142239,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":824347356,"gmtCreate":1634285269415,"gmtModify":1634285269415,"author":{"id":"3569809505691000","authorId":"3569809505691000","name":"breAkdaWn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Better take Xanax!","listText":"Better take Xanax!","text":"Better take Xanax!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824347356","repostId":2175194207,"repostType":4,"repost":{"id":"2175194207","pubTimestamp":1634264640,"share":"https://www.laohu8.com/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":824341402,"gmtCreate":1634284919851,"gmtModify":1634284919939,"author":{"id":"3569485137179617","authorId":"3569485137179617","name":"carchoo","avatar":"https://static.tigerbbs.com/3321d05dd84c0832a063600962a1c079","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Ok cool&nbsp;","listText":"Ok cool&nbsp;","text":"Ok cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824341402","repostId":2175194207,"repostType":4,"repost":{"id":"2175194207","pubTimestamp":1634264640,"share":"https://www.laohu8.com/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":824307283,"gmtCreate":1634276289980,"gmtModify":1634276290422,"author":{"id":"4091932914422900","authorId":"4091932914422900","name":"Abbas99m","avatar":"https://static.tigerbbs.com/a026254fe4800d31971dee7f5e269073","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824307283","repostId":2175194207,"repostType":4,"repost":{"id":"2175194207","pubTimestamp":1634264640,"share":"https://www.laohu8.com/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6209384,"gmtCreate":1634288056824,"gmtModify":1634634922675,"authorId":4091089381144950,"author":{"id":4091089381144950,"authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":824307283,"type":1,"supId":0,"prevId":0,"content":"Okly","text":"Okly","html":"Okly"}],"langContent":"CN"},{"id":824977577,"gmtCreate":1634275205958,"gmtModify":1634275206115,"author":{"id":"3579235597126488","authorId":"3579235597126488","name":"Cvt","avatar":"https://static.tigerbbs.com/c8fda02901ec7a98b51fe8e84d016ab2","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824977577","repostId":2175194207,"repostType":4,"repost":{"id":"2175194207","pubTimestamp":1634264640,"share":"https://www.laohu8.com/m/news/2175194207?lang=&edition=full","pubTime":"2021-10-15 10:24","market":"us","language":"en","title":"1 Beaten-Down Stock With 10X Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2175194207","media":"Motley Fool","summary":"This biotech is down, but it isn't out just yet.","content":"<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially <a href=\"https://laohu8.com/S/AONE.U\">one</a> with a relatively small stock market capitalization.</p>\n<p>Of course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, <b>Axsome Therapeutics</b> (NASDAQ:AXSM), and consider why this company still has some serious potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e718d88c283ce5cf7cc7b8239f5cdcf4\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>AXSM data by YCharts.</span></p>\n<h2>A series of setbacks</h2>\n<p>Axsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.</p>\n<p>Then the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.</p>\n<p>But because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome.&nbsp;The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.</p>\n<h2>Why Axsome Therapeutics' shares could soar</h2>\n<p>Despite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.</p>\n<p>There are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.</p>\n<p>Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.</p>\n<p>True, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony.&nbsp;The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.</p>\n<p>Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.</p>\n<h2>Bargain hunters need not look elsewhere</h2>\n<p>With Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.</p>\n<p>On the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.</p>\n<p>Given the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Beaten-Down Stock With 10X Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Beaten-Down Stock With 10X Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/1-beaten-down-stock-with-10x-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175194207","content_text":"Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization.\nOf course, these companies also have their risks, so picking the right drugmaker is key to making market-shattering gains in the long run. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ:AXSM), and consider why this company still has some serious potential.\nAXSM data by YCharts.\nA series of setbacks\nAxsome Therapeutics has encountered a couple of regulatory obstacles of late. On July 13, the company announced that the U.S. Food and Drug Administration (FDA) had decided to rescind the breakthrough designation for AXS-12, a potential treatment for catalepsy (loss of muscle control) in narcolepsy patients. A breakthrough designation helps speed up the review process for drugs intended to treat a severe condition. The FDA's decision came after it approved a competing medicine for catalepsy.\nThen the review of Axsome Therapeutics' application for AXS-05 hit a speed bump. AXS-05 is a potential treatment for major depressive disorder. The FDA had initially set a date for completing its review -- known as the PDUFA goal date -- of Aug. 22.\nBut because of deficiencies in the company's application, regulators were unable to complete the review of the drug by this date. The good news is that the FDA did not request additional information from Axsome. The bad news is that we still don't know when the agency will complete its review of the application and what its outcome will be.\nWhy Axsome Therapeutics' shares could soar\nDespite these issues, Axsome could be a great long-term bet. Let's look at the potential that AXS-05 offers. Depression is a serious issue that affects millions of people, and it has been exacerbated by the pandemic. Before the outbreak, 22 million people in the U.S. showed symptoms of depression. That number has almost quadrupled to 80 million.\nThere are certainly existing ways to manage this illness, but AXS-05 could be more effective. The drug significantly reduced symptoms of depression in a phase 3 clinical trial, and the FDA granted it \"priority review\" in this indication. The agency reserves the \"priority review\" designation for drugs that would be an improvement over current therapy options for an illness.\nAxsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential treatment for Alzheimer's disease agitation (aggressive and erratic behavior), an indication that could bring the company $3 billion in sales.\nTrue, the current regulatory issues surrounding this drug render its future uncertain, but Axsome isn't a one-trick pony. The company has several other promising pipeline programs. There is AXS-07, an investigational therapy for migraines. Axsome recently announced that the FDA had accepted its application for this drug and set a PDUFA goal date of April 30, 2022. Peak sales for this medicine could be between $500 million and $1 billion, according to the company.\nAxsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also needs to be factored into the company's outlook. While the proposed drug lost its \"breakthrough\" designation, it remains under FDA consideration.\nBargain hunters need not look elsewhere\nWith Axsome's market capitalization standing at $1.2 billion, investors appear to have little faith the company can generate the kind of sales it predicts from its programs -- and they could be right. There are certainly regulatory risks to consider.\nOn the positive side, Axsome had a cash and equivalents balance of $141.2 million. That, combined with capital remaining from a $225 million term-loan facility it secured in September 2020, should be enough to fund operations until at least 2024, according to management.\nGiven the biotech company's current valuation and potential pipeline, it could provide explosive gains for investors who get in at these levels. However, be advised: There will be lots of volatility along the way. Invest accordingly.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":160,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2175194207"}